Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Pharma Industry Analysis

UpdatedMar 26, 2026
DataAggregated Company Financials
Companies41
  • 7D-1.7%
  • 3M7.3%
  • 1Y21.6%
  • YTD5.6%

Over the last 7 days, the Pharma industry has dropped 4.2%, driven by Chugai Pharmaceutical declining 5.9%. Over the past 12 months, the industry was up 19%. Looking forward, earnings are forecast to grow by 9.5% annually.

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 26 Mar 2026JP¥49.8tJP¥17.3tJP¥2.2t15.9x22.8x2.9x
Sat, 21 Feb 2026JP¥52.5tJP¥17.3tJP¥2.2t15.9x24.1x3x
Mon, 19 Jan 2026JP¥47.0tJP¥16.9tJP¥1.9t16.7x24.6x2.8x
Wed, 17 Dec 2025JP¥45.7tJP¥16.9tJP¥1.9t16.2x24x2.7x
Fri, 14 Nov 2025JP¥43.8tJP¥16.9tJP¥1.9t15.5x22.8x2.6x
Sun, 12 Oct 2025JP¥42.5tJP¥16.8tJP¥1.8t15.4x23.3x2.5x
Tue, 09 Sep 2025JP¥42.3tJP¥16.8tJP¥1.8t16.3x23.1x2.5x
Thu, 07 Aug 2025JP¥41.6tJP¥16.8tJP¥1.8t17.1x22.5x2.5x
Sat, 05 Jul 2025JP¥39.4tJP¥16.8tJP¥1.8t15x22.4x2.3x
Mon, 02 Jun 2025JP¥41.3tJP¥16.8tJP¥1.8t14.8x23.3x2.4x
Wed, 30 Apr 2025JP¥40.6tJP¥16.7tJP¥1.7t15x24x2.4x
Fri, 28 Mar 2025JP¥41.0tJP¥16.5tJP¥1.5t15.9x27.3x2.5x
Sun, 23 Feb 2025JP¥40.4tJP¥16.5tJP¥1.5t15.8x26.9x2.5x
Tue, 21 Jan 2025JP¥40.9tJP¥16.1tJP¥1.4t15.3x29.1x2.5x
Thu, 19 Dec 2024JP¥41.6tJP¥16.1tJP¥1.4t14.7x29.4x2.6x
Sat, 16 Nov 2024JP¥43.9tJP¥16.1tJP¥1.4t15.1x31.1x2.7x
Mon, 14 Oct 2024JP¥44.9tJP¥15.6tJP¥1.2t15.9x37.4x2.9x
Wed, 11 Sep 2024JP¥44.6tJP¥15.5tJP¥1.2t17.3x37.1x2.9x
Fri, 09 Aug 2024JP¥43.0tJP¥15.5tJP¥1.2t16.3x35.8x2.8x
Sun, 07 Jul 2024JP¥43.9tJP¥15.0tJP¥1.1t18.5x40.1x2.9x
Tue, 04 Jun 2024JP¥40.8tJP¥15.0tJP¥1.1t17.9x37.3x2.7x
Thu, 02 May 2024JP¥41.0tJP¥14.9tJP¥1.3t18.9x32.8x2.7x
Sat, 30 Mar 2024JP¥42.2tJP¥15.1tJP¥1.2t20.1x34.7x2.8x
Mon, 26 Feb 2024JP¥42.1tJP¥15.1tJP¥1.2t20.6x34.6x2.8x
Wed, 24 Jan 2024JP¥41.6tJP¥15.2tJP¥1.4t19.9x30.2x2.7x
Fri, 22 Dec 2023JP¥38.3tJP¥15.2tJP¥1.4t19.2x27.8x2.5x
Sun, 19 Nov 2023JP¥39.1tJP¥15.2tJP¥1.4t19.9x28.4x2.6x
Tue, 17 Oct 2023JP¥39.8tJP¥14.9tJP¥1.4t24x27.9x2.7x
Thu, 14 Sep 2023JP¥40.8tJP¥14.9tJP¥1.4t24.3x28.6x2.7x
Sat, 12 Aug 2023JP¥40.5tJP¥14.9tJP¥1.4t22.9x28.4x2.7x
Mon, 10 Jul 2023JP¥38.3tJP¥14.6tJP¥1.5t20.2x26.2x2.6x
Wed, 07 Jun 2023JP¥41.5tJP¥14.6tJP¥1.5t20.3x28.4x2.8x
Fri, 05 May 2023JP¥39.2tJP¥14.5tJP¥1.4t18.7x27.6x2.7x
Sun, 02 Apr 2023JP¥37.4tJP¥14.3tJP¥1.5t16.9x25.5x2.6x
Price to Earnings Ratio

25.5x


Total Market Cap: JP¥37.4tTotal Earnings: JP¥1.5tTotal Revenue: JP¥14.3tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Pharma Industry Price to Earnings3Y Average 28.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.3x which is lower than its 3-year average PE of 28.7x.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 14% per year over the last three years.
  • Revenues for these companies have grown 6.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?

JP Market-1.93%
Healthcare-1.14%
Pharma-1.65%
Pharma-1.65%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4503 Astellas PharmaJP¥2.54k3.8%
+JP¥164.8b		69.7%PE14.1x
4506 Sumitomo PharmaJP¥1.99k5.6%
+JP¥42.1b		169.3%PE7.2x
4528 Ono PharmaceuticalJP¥2.46k2.1%
+JP¥23.7b		45.9%PE18.5x
4151 Kyowa KirinJP¥2.44k1.1%
+JP¥13.6b		12.5%PE19.1x
4536 Santen PharmaceuticalJP¥1.73k2.4%
+JP¥13.2b		19.9%PE18.2x

Latest News

4519
JP¥8,462.00
Chugai Pharmaceutical
7D
-5.8%
1Y
19.3%

4519: Rich P/E And Clinical Setbacks Will Likely Restrain Future Upside

Analysts have nudged their price target for Chugai Pharmaceutical down from ¥6,584.94 to ¥6,400. This change reflects updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple.
4523
JP¥4,872.00
Eisai
7D
-1.5%
1Y
12.8%
4507
JP¥3,441.00
Shionogi
7D
-1.9%
1Y
47.7%
4503
JP¥2,538.50
Astellas Pharma
7D
3.8%
1Y
69.7%
4536
JP¥1,731.00
Santen Pharmaceutical
7D
2.4%
1Y
19.9%
4502
JP¥5,820.00
Takeda Pharmaceutical
7D
-0.9%
1Y
28.4%
4521
JP¥4,175.00
Kaken Pharmaceutical
7D
-2.8%
1Y
-9.0%
4887
JP¥2,260.00
Sawai Group Holdings
7D
3.2%
1Y
7.8%
4534
JP¥3,670.00
Mochida Pharmaceutical
7D
1.9%
1Y
9.6%
4528
JP¥2,461.00
Ono Pharmaceutical
7D
2.1%
1Y
45.9%
4578
JP¥10,970.00
Otsuka Holdings
7D
-1.3%
1Y
36.2%

4578: Future Repricing Will Rely On Morgan Stanley Upgrade And Capital Returns

Analysts have raised their price target for Otsuka Holdings from ¥12,600 to about ¥14,603, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E following recent research including the Morgan Stanley upgrade. Analyst Commentary Recent research has drawn attention to Otsuka Holdings as bullish analysts revisit their assumptions around discount rate, revenue growth, profit margin and future P/E.
4568
JP¥2,974.00
Daiichi Sankyo Company
7D
-0.1%
1Y
-20.1%

4568: Priority Oncology Filings And Reviews Will Drive Future Upside Potential

Analysts have trimmed their price target for Daiichi Sankyo Company from ¥6,300 to ¥6,000, reflecting slightly lower modeled revenue growth, a modest adjustment to profit margins, and a small uptick in the discount rate and future P/E assumptions in their updated forecasts. What's in the News The U.S. FDA accepted and granted Priority Review to a supplemental Biologics License Application for ENHERTU for certain HER2 positive early breast cancer patients with residual invasive disease after neoadjuvant therapy, with a target decision date of July 7, 2026, under Project Orbis (Key Developments).
4151
JP¥2,441.00
Kyowa Kirin
7D
1.1%
1Y
12.5%
4565
JP¥879.00
Nxera Pharma
7D
-4.0%
1Y
-6.5%
4506
JP¥1,992.50
Sumitomo Pharma
7D
5.6%
1Y
169.3%
4888
JP¥840.00
Stella Pharma
7D
50.0%
1Y
109.0%